DE60236965D1 - Coronavirus-ähnliche partikel enthaltende funktionell deletierte genome - Google Patents
Coronavirus-ähnliche partikel enthaltende funktionell deletierte genomeInfo
- Publication number
- DE60236965D1 DE60236965D1 DE60236965T DE60236965T DE60236965D1 DE 60236965 D1 DE60236965 D1 DE 60236965D1 DE 60236965 T DE60236965 T DE 60236965T DE 60236965 T DE60236965 T DE 60236965T DE 60236965 D1 DE60236965 D1 DE 60236965D1
- Authority
- DE
- Germany
- Prior art keywords
- coronavirus
- particles containing
- similar particles
- functionally deleted
- containing functionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
- A61K39/225—Porcine transmissible gastroenteritis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20041—Use of virus, viral particle or viral elements as a vector
- C12N2770/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01201861 | 2001-05-17 | ||
PCT/NL2002/000318 WO2002092827A2 (en) | 2001-05-17 | 2002-05-17 | Corona-virus-like particles comprising functionally deleted genomes |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60236965D1 true DE60236965D1 (de) | 2010-08-19 |
Family
ID=8180327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60236965T Expired - Lifetime DE60236965D1 (de) | 2001-05-17 | 2002-05-17 | Coronavirus-ähnliche partikel enthaltende funktionell deletierte genome |
Country Status (16)
Country | Link |
---|---|
US (1) | US20040071709A1 (de) |
EP (1) | EP1470218B1 (de) |
JP (1) | JP4463481B2 (de) |
CN (1) | CN100580080C (de) |
AT (1) | ATE473274T1 (de) |
AU (1) | AU2002311668B2 (de) |
BR (1) | BR0209837A (de) |
CA (1) | CA2447450C (de) |
DE (1) | DE60236965D1 (de) |
ES (1) | ES2348600T3 (de) |
HU (1) | HU228121B1 (de) |
MX (1) | MXPA03010427A (de) |
NZ (1) | NZ529691A (de) |
PL (1) | PL207933B1 (de) |
WO (1) | WO2002092827A2 (de) |
ZA (1) | ZA200309098B (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7556957B2 (en) | 2001-05-17 | 2009-07-07 | Stichting Voor De Technische Wetenschappen | Coronavirus-like particles comprising functionally deleted genomes |
JP4242607B2 (ja) * | 2002-07-04 | 2009-03-25 | 学校法人北里研究所 | ネコ伝染性腹膜炎ワクチン |
DE602004023594D1 (de) | 2003-03-03 | 2009-11-26 | Inst Animal Health Newbury | Ein virus der infektiösen bronchitis mit veränderten spike-gen |
DE602004025689D1 (de) * | 2003-04-28 | 2010-04-08 | Sequoia Pharmaceuticals Inc | Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren |
WO2004106497A2 (en) * | 2003-05-27 | 2004-12-09 | Anticancer, Inc. | Imageable animal model of sars infection |
WO2004110483A1 (en) * | 2003-05-31 | 2004-12-23 | Yiyou Chen | Method and composition of a novel vaccine design for the prevention and treatment of sars |
WO2005012360A2 (en) * | 2003-07-22 | 2005-02-10 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
CN1324049C (zh) * | 2003-08-04 | 2007-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗sars冠状病毒基因工程抗体 |
WO2005017133A1 (en) † | 2003-08-18 | 2005-02-24 | Amsterdam Institute Of Viral Genomics B.V. | Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics |
EP2361974A1 (de) * | 2003-12-02 | 2011-08-31 | Institut Pasteur | Verwendung von Proteinen und Peptiden, kodiert im Genom eines neuen mit SARS verbunden coronavirus Stammes |
WO2005077103A2 (en) * | 2004-02-12 | 2005-08-25 | Regents Of The University Of Colorado | Compositions and methods for modification and prevention of sars coronavirus infectivity |
US20060199176A1 (en) * | 2004-07-15 | 2006-09-07 | Yeau-Ching Wang | Coronavirus S peptides |
EP1650308A1 (de) * | 2004-09-03 | 2006-04-26 | Consejo Superior De Investigaciones Cientificas | Nukleinsäuresequenzen kodierend für Proteine, die Virus-ähnliche Partikel bilden können |
EP2295590A1 (de) | 2004-09-03 | 2011-03-16 | Consejo Superior De Investigaciones Cientificas | Nukleinsaüresequenzen kodierend für Proteinen, die Virus-ähnlichen Partikeln bilden können |
KR100915980B1 (ko) | 2004-11-26 | 2009-09-10 | 디엔에이 셔틀 바이오팜 컴퍼니, 엘티디. | 코로나바이러스-유사 입자를 인코딩하는 발현 벡터 |
RU2383621C2 (ru) * | 2004-11-26 | 2010-03-10 | Ди-Эн-Эй ШАТТЛ БАЙОФАРМ КО., ЛТД. | Экспрессирующий вектор, кодирующий coronavirus-подобную частицу |
EP1792996A1 (de) * | 2005-12-01 | 2007-06-06 | Consejo Superior de Investigaciones Cientificas | Nukleinsäuren, kodierend für Impfstoffe gegen den reproduktiven und respiratorischen Syndrom Virus (prrsv) |
US20120064115A1 (en) * | 2009-05-01 | 2012-03-15 | Corinne John | Recombinant virus-like particles encoded by multi-gene vector |
EA201201620A1 (ru) * | 2010-06-02 | 2013-07-30 | Авир Грин Хилз Байотекнолоджи Рисерч Дивелопмент Трейд Аг | Способ получения рнк-вируса |
CN103316337B (zh) * | 2010-08-30 | 2014-08-13 | 中国人民解放军军事医学科学院微生物流行病研究所 | 痘苗病毒载体基因修饰系统的建立及重组冠状病毒的应用 |
CN101948516B (zh) * | 2010-08-30 | 2013-05-01 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种以痘苗病毒载体为基础的反向遗传学系统建立及应用 |
EP2681232A1 (de) * | 2011-03-02 | 2014-01-08 | Intervet International B.V. | Spike-protein eines infektiösen bronchitis-virus (ibv) als untereinheitsimpfstoff |
EP2825560A1 (de) * | 2012-03-13 | 2015-01-21 | Universiteit Utrecht Holding BV | Bispezifische adapter |
CN107075487A (zh) | 2014-08-08 | 2017-08-18 | 乌得勒支大学控股有限公司 | 突变的猪流行性腹泻病毒用于在疫苗中的用途 |
GB201601498D0 (en) * | 2016-01-27 | 2016-03-09 | Pirbright Inst The | Coronavirus |
CN112300251B (zh) * | 2020-02-24 | 2022-04-05 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2感染的蛋白及疫苗 |
US20230192786A1 (en) * | 2020-05-15 | 2023-06-22 | Glg Pharma, Llc | Stat3 inhibition for treatment and prevention of human coronavirus infection |
CN111732637B (zh) * | 2020-05-25 | 2022-03-01 | 上海交通大学 | 抑制新型冠状病毒SARS-CoV-2感染宿主细胞的多肽及其应用 |
IL300905A (en) * | 2020-08-27 | 2023-04-01 | Univ Leland Stanford Junior | Immunogenic fusion proteins from the corona virus, preparations containing them and their uses |
CN112250738B (zh) * | 2020-09-02 | 2023-05-12 | 兰州大学 | 严重急性呼吸综合征冠状病毒2病毒样颗粒的制备、纯化和鉴定方法 |
US11479582B2 (en) | 2020-10-16 | 2022-10-25 | King Faisal University | Anti-SARS-CoV-2 fusion peptides |
US20230408515A1 (en) * | 2020-11-10 | 2023-12-21 | Massachusetts Institute Of Technology | Engineered protein for rapid, efficient capture of pathogen-specific antibodies |
CN113151359A (zh) * | 2020-12-25 | 2021-07-23 | 广州医科大学 | 一种冠状病毒的缺陷型嵌合病毒模型的包装体系及其应用 |
CN112852762B (zh) | 2021-04-02 | 2021-09-10 | 青岛海华生物医药技术有限公司 | 新型冠状病毒肺炎副粘病毒疫苗株及其构建方法 |
CN113713122A (zh) * | 2021-08-24 | 2021-11-30 | 华中科技大学 | 一种与新冠病毒竞争性结合细胞表面受体的超分子 |
CN116042538A (zh) * | 2022-11-24 | 2023-05-02 | 华中农业大学 | 一株猫冠状病毒及其应用 |
CN116808193B (zh) * | 2023-08-29 | 2023-11-14 | 成都导飞科技有限公司 | 一种用于预防猫传染性腹膜炎的重组蛋白疫苗及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998049195A1 (en) * | 1997-04-29 | 1998-11-05 | Universiteit Utrecht | Corona virus-like particles as tools for vaccination and therapy |
ES2170622B1 (es) * | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
-
2002
- 2002-05-17 CA CA2447450A patent/CA2447450C/en not_active Expired - Lifetime
- 2002-05-17 ES ES02738952T patent/ES2348600T3/es not_active Expired - Lifetime
- 2002-05-17 DE DE60236965T patent/DE60236965D1/de not_active Expired - Lifetime
- 2002-05-17 AT AT02738952T patent/ATE473274T1/de not_active IP Right Cessation
- 2002-05-17 HU HU0400042A patent/HU228121B1/hu unknown
- 2002-05-17 WO PCT/NL2002/000318 patent/WO2002092827A2/en active Application Filing
- 2002-05-17 AU AU2002311668A patent/AU2002311668B2/en not_active Expired
- 2002-05-17 PL PL374582A patent/PL207933B1/pl unknown
- 2002-05-17 NZ NZ529691A patent/NZ529691A/en not_active IP Right Cessation
- 2002-05-17 EP EP02738952A patent/EP1470218B1/de not_active Expired - Lifetime
- 2002-05-17 BR BR0209837-7A patent/BR0209837A/pt not_active IP Right Cessation
- 2002-05-17 MX MXPA03010427A patent/MXPA03010427A/es active IP Right Grant
- 2002-05-17 CN CN02814378A patent/CN100580080C/zh not_active Expired - Lifetime
- 2002-05-17 JP JP2002589693A patent/JP4463481B2/ja not_active Expired - Fee Related
-
2003
- 2003-04-14 US US10/414,256 patent/US20040071709A1/en not_active Abandoned
- 2003-11-21 ZA ZA2003/09098A patent/ZA200309098B/en unknown
Also Published As
Publication number | Publication date |
---|---|
PL207933B1 (pl) | 2011-02-28 |
WO2002092827A3 (en) | 2004-05-27 |
EP1470218A2 (de) | 2004-10-27 |
MXPA03010427A (es) | 2004-12-06 |
PL374582A1 (en) | 2005-10-31 |
CN1620500A (zh) | 2005-05-25 |
HU228121B1 (en) | 2012-11-28 |
WO2002092827A2 (en) | 2002-11-21 |
CA2447450A1 (en) | 2002-11-21 |
ZA200309098B (en) | 2005-04-26 |
NZ529691A (en) | 2007-12-21 |
US20040071709A1 (en) | 2004-04-15 |
EP1470218B1 (de) | 2010-07-07 |
ES2348600T3 (es) | 2010-12-09 |
JP4463481B2 (ja) | 2010-05-19 |
JP2005503132A (ja) | 2005-02-03 |
HUP0400042A2 (hu) | 2004-04-28 |
CA2447450C (en) | 2011-12-20 |
HUP0400042A3 (en) | 2011-07-28 |
ATE473274T1 (de) | 2010-07-15 |
AU2002311668B2 (en) | 2007-10-04 |
BR0209837A (pt) | 2004-12-14 |
CN100580080C (zh) | 2010-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60236965D1 (de) | Coronavirus-ähnliche partikel enthaltende funktionell deletierte genome | |
ATE478944T1 (de) | Zytokin ligand zur behandlung von asthma und atemwegsüberreaktivität | |
WO2005066204A3 (en) | Neutralizing epitope-based growth enhancing vaccine | |
ATE369144T1 (de) | Verfahren zur steigerung des haarwuchses durch wnt polypeptid | |
NO20063026L (no) | Antistoffer | |
NZ595736A (en) | Chimeric viruses presenting non-native surface proteins and uses thereof | |
DK1062226T3 (da) | Nukleinsyreligander med høj affinitet mod komplementsystemets C5-protein | |
DK1355949T3 (da) | Antistoffer mod konformationelt abnorme former af tau-protein der forekommer i væv ved Alzheimers sygdom | |
CY1109725T1 (el) | Ειδικες δεσμευομενες πρωτεϊνες και χρησεις αυτων | |
MXPA03000626A (es) | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c. | |
TW200510450A (en) | Soluble fragments of the SARS-CoV spike glycoprotein | |
WO2005016132A3 (en) | Diagnostics for sars virus | |
JP2002505841A5 (de) | ||
WO2005056585A3 (en) | Sars coronavirus s proteins and uses thereof | |
ATE319439T1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
EP1610678A4 (de) | Antikörper und diese enthaltende pharmazeutische zusammensetzungen zur hemmung der aktivität von metalloproteinen | |
ATE300619T1 (de) | Humane checkpointkinase, hcds1, zusammensetzungen und verfahren | |
ATE406449T1 (de) | Antigene und vektoren für impfung | |
WO2005063801A3 (en) | Method for decreasing the contact between hepta-repeat region s of the corona-virus spike proteins and use thereof | |
WO2004110349A3 (en) | Sars t cell epitopes and methods for identifying same | |
ATE370160T1 (de) | Peptide mit affinität zu gp120, und ihre verwendungen | |
ATE543513T1 (de) | Anti-coronavirus impfstoff | |
ATE529530T1 (de) | Rekombinante antikörper zum nachweis und zur neutralisierung von milzbrandtoxin | |
DE60032915D1 (de) | Gallium komplexe von 3-hydroxy-4-pyronen zur behandlung von durch intrazelluläre prokaryoten, dns- und retro-viren verursachten infektionen | |
FR2815634B1 (fr) | Anticorps monoclonaux diriges contre des virus de l'hepatite b |